Clinical TrialJul 14, 2026, 04:26 PM
CervoMed Presents New Clinical Data for Neflamapimod in DLB
AI Summary
CervoMed Inc. announced new clinical, plasma biomarker, and imaging data for its lead drug candidate, neflamapimod, in treating Dementia with Lewy Bodies (DLB) at the Alzheimer's Association International Conference 2026. New analyses from the Phase 2b RewinD-LB trial reinforced the treatment effect in "pure" DLB patients and supported the selection of a 50 mg TID dose for the planned Phase 3 study. The data also showed neflamapimod durably slowed basal forebrain atrophy and increased connectivity, while a new Phase 2 study of an 80 mg BID dose met safety and pharmacokinetic objectives with encouraging clinical activity. These findings provide important insights for the upcoming Phase 3 trial.
Key Highlights
- New analyses of Phase 2b RewinD-LB trial data presented at AAIC 2026.
- Neflamapimod 50 mg TID dose selected for planned Phase 3 study in DLB.
- Neflamapimod showed durable slowing of basal forebrain atrophy over 48 weeks.
- New Phase 2 study of neflamapimod 80 mg BID met primary safety and PK objectives.
- Plasma Ctrough threshold of ~4 ng/mL associated with biomarker and clinical improvements.
- Planned 50 mg TID dose expected to achieve Ctrough threshold in ~90% of patients.
- Dementia with Lewy Bodies (DLB) is the second most common progressive dementia.
Price Impact
More from CRVO